Global COVID-19 cases stabilize as deaths drop – CIDRAP

AMISOM, Fardosa Hussein / Flickr cc
After a 5-week drop, global COVID-19 cases stabilized last week, though deaths continued to decline, the World Health Organization (WHO) said today in its weekly update on the pandemic.
Cases were down in all but one of the six world regions, with the biggest drop in African countries (-35%). Cases were up 3% in the Western Pacific and down only 1% in Europe.
Of more than 3.2 million new cases reported last week, the five countries reporting the most were Japan, the United States, South Korea, Russia, and China. In the previous week, officials reported 3.1 million new COVID cases.
Meanwhile, deaths declined 17% from the previous week, with countries reporting more than 9,800 fatalities to the WHO.
The WHO has urged caution in interpreting COVID patterns, given decreases in testing and fewer SARS-CoV-2 sequences submitted for analysis.
In its latest update on variants, the WHO said the Omicron variant continues to dominate and become more diversified. There are now more than 230 Omicron descendants and more than 30 recombinants. During the final days of August and into September, the BA.5 subvariant made up 76.6% of sequences, with BA.4 accounting for 7.5%.
The WHO is closely tracking six Omicron subvariant lineages, with proportions of BA.2.75—with its nine extra spike mutations—low but rising. So far, 48 countries have detected it, with most sequences reported from India. BA.2.75.2 has three additional spike mutations, and the United States is among the countries in which levels are slowly increasing.
Officials are also monitoring other emerging BA.5 subvariants that have spread to new locations. So far, prevalence is low, but numbers have been rising over the past 4 weeks.
Amid reports of shortages of Moderna’s updated booster shots, the agency will soon release 10 million doses that were held back due to safety reviews at an Indiana plant that is bottling the packaging the product, according to the Washington Post.
Last month, inspectors raised questions about sterility and checked for contamination as part of routine safety reviews, unnamed people with knowledge of the process told the Post.
FDA spokesman Michael Felberbaum told the Post that yesterday, the US Food and Drug Administration (FDA) authorized distribution of numerous batches of the updated Moderna booster that were packaged at the Catalent facility in Bloomington. He added that the FDA has no concerns about the safety, effectiveness, and quality of the batches.
Federal officials have pinned their hopes for avoiding a new COVID surge by quickly rolling out doses of the updated booster shots.
Americans with ADHD are struggling to find good alternatives to the stimulant Adderall.
The bivalent booster marshaled a robust antibody response against the Omicron BA.4/BA.5 subvariants but not against the more recently emerged variants.
People around the world who are vaccinated against COVID-19 look down on the unvaccinated as much or more than they do often-marginalized groups, while the unvaccinated display little rancor toward the vaccinated.
Rebound was uncommon after use of the oral antivirals Paxlovid and molnupiravir to lower the risk of severe outcomes.
The BQ.1.1 and XBB SARS-CoV-2 subvariants evade monoclonal antibodies but not the antiviral drugs remdesivir, molnupiravir, and Paxlovid.
Protection was 35% among those vaccinated before contracting COVID-19.
Symptoms overall declined in a year, but some had symptoms for the first time at 6 and 12 months.
As the holidays approach, the flu surge continues, and tracking shows a fresh spike in COVID-19 markers.
Swedish study shows ICU patients most likely to experience long COVID.
Groups representing infectious disease and public health professionals and the pharmaceutical industry are trying to push a bill across the finish line that could change the antibiotic development landscape.
Help make CIDRAP’s vital work possible
CIDRAP – Center for Infectious Disease Research & Policy
Office of the Vice President for Research, University of Minnesota, Minneapolis, MN
Email us
© 2022 Regents of the University of Minnesota. All rights Reserved.
The University of Minnesota is an equal opportunity educator and employer
Office of the Vice President for Research |   Contact U of M  |  Privacy Policy
Newsletter subscribe